The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.
Data From the SOFT and TEXT Trials: Combination Therapy With OFS in Breast Cancer
Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the SOFT and TEXT clinical trials to elucidate combination treatment strategies with ovarian function suppression (OFS).
Watch
Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.
Watch
Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer
The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.
Watch
Dr Coopey on the Benefits of Axillary Surgery Omission or De-Escalation in Breast Cancer
June 29th 2023Suzanne B. Coopey, MD, FACS, discusses the benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer, as well as current recommendations for the de-escalation or omission of this procedure.
Watch
Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities
Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.
Watch
Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.
Watch
Fertility Preservation in Breast Cancer: Use of GnRH Agonists
Comprehensive insight to available gonadotropin-releasing hormone (GnRH) agonists in breast cancer and the role they play when thinking about fertility preservation.
Watch
Overview of Fertility Preservation Strategies in Breast Cancer Care
Key opinion leaders on breast cancer management provide a broad overview of fertility preservation strategies available to patients.
Watch
Investigation of Pembrolizumab De-Escalation After pCR Aims to Challenge SOC in Early-Stage TNBC
June 27th 2023Yuan Yuan, MD, PhD, discusses the OptimICE-pCR trial and other ongoing clinical trials in breast cancer being conducted at Cedars-Sinai, and expands on the role of CDK4/6 inhibitors and other novel treatment strategies for patients with hormone receptor-positive breast cancer.
Read More
Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer
A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.
Watch
SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
June 24th 2023The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors plus an aromatase inhibitor followed by fulvestrant.
Read More
Sacituzumab Govitecan Approaches EU Approval for Pretreated HR+ Metastatic Breast Cancer
June 23rd 2023The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan-hziy monotherapy in select patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.
Read More
Dr Hamilton on the Investigation of HER3-DXd in ER+ Breast Cancer and TNBC
June 23rd 2023Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.
Watch
Addressing Chemotherapy-Induced Menopause in Patients With Breast Cancer
Focused discussion on the incidence of chemotherapy-induced menopause in patients receiving treatment for their breast cancer.
Watch
Prevalence of Premenopausal Patients With Breast Cancer
Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the subset of patients with breast cancer who are premenopausal and how that impacts their approach to disease management.
Watch
Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer
June 19th 2023Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.
Watch